EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG: Licensing Partner Quest Diagnostics Introduces Colorectal Cancer Blood Test in the U.S.

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products/Molecular diagnostics

11.01.2010

Berlin, January 11, 2010 - Epigenomics AG (ISIN: DE000A0BVT96), a
cancer molecular diagnostics company, informs that Quest Diagnostics
Incorporated, Madison, NJ, U.S.A., today introduced its laboratory
developed blood test for aiding the detection of colorectal cancer in
the United States. The test was independently developed by Quest
Diagnostics based on Epigenomics´ proprietary DNA methylation
biomarker Septin9 and certain proprietary technologies that were
licensed to Quest Diagnostics in 2008. The introduction follows the
successful completion of the clinical validation of this laboratory
developed test in November 2009 and the release of the test for
offering to doctors and patients in December 2009.

Physicians in the United States may order the test through a Quest
Diagnostics regional laboratory. With the introduction of this test,
Epigenomics continues executing its dual business model of
non-exclusive licensing and direct commercialization of its cancer
molecular diagnostic biomarkers and products.

End of Ad hoc

Further Information

For further information please see today´s press release by Quest
Diagnostics at
http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irol-news

Epigenomics legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward- looking statements contained herein as a result of new
information, future events or otherwise.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade